N/A N=214 Correlational Study on the Biomarkers Application to the Prediction and Diagnosis of Cardiovascular Diseases
Stable Angina
Primary: Biomarker Titer of Patients With Coronary Artery Disease — 13; 5; 60; 0.5 tilter — p=0.002
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=132 Biomarkers in Thoracic Aorta Surgery
Aortic Aneurysm · Thoracoabdominal Aneurysm · Aortic Dissection
Primary: Number of Total Postoperative Complications — 69 post-operative complications
N/A N=15 Biomarkers of Intestinal Mucosal Healing in Crohn's Disease (P08143)
Crohn Disease
Primary: Change From Baseline in the Crohn's Disease Endoscopic Index of Severity (CDEIS) Blinded Score at Week 6 — -4.8 Score on a scale
N/A N=165 Biomarkers in First Episode Schizophrenia
Schizophrenia · Schizophreniform Disorder · Schizoaffective Disorder, Depressed Type
Primary: Biomarkers — 287.37; 340.83; 492.33; 420.17 pg/mL
Phase 1 N=31 A Study to Evaluate Biomarkers in Patients With Solid Tumors (0000-097)(COMPLETED)
Tumors
Primary: Level of Biomarkers — 24.6; NA; 34.3; 23.0 Percent pCDC2-positive cells
N/A N=70 Lipid Biomarkers for Diabetic Heart Disease
Type II Diabetes Mellitus · Diabetes Complications
Primary: Change in Cardiac Diastolic Function as Measured by E' (cm/s) — -0.02; 0.55 cm/s — p=0.07
Phase 4 N=121 Glaucoma Biomarkers
Glaucoma · Healthy
Primary: Variation in Eye Pressure Between Individuals. — 11.5; 11.3; 11.0; 11.0 mmHg — p=0.0001
Phase 4 N=53 Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease
Alzheimer Disease
Primary: Change From Baseline Measure in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog) at 8, 16 and 24 Weeks — 19.76; 19.81; 19.94; 20.79 scores on a scale…
Phase 2 N=16 Biomarkers in Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: PANSS Total — 77.9; 80 units on a scale — p=0.02
Phase 4 N=347 Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment
Idiopathic Pulmonary Fibrosis
Primary: The Rate of Change (Slope) in Blood C-reactive Protein Degraded by Matrix Metalloproteinase-1/8 (CRPM) From Baseline to Week 12. — -0.00190; -0.00257 nanogram/ millitre/…
Phase 2 N=58 Biomarker Guided Therapies in Stage A/B Heart Failure
Hypertension · Diabetes · Cardiovascular Disease
Primary: Change in Cardiac Global Longitudinal Strain — -1.4; -1.74; -1.14 % systolic deformation
N/A N=45 Biomarkers of Anti-TNF Treatment in Inflammatory Bowel Disease (IBD)
Inflammatory Bowel Diseases
Primary: Pre-treatment Serum Level of Endogenous Anti-TNF in Relation to Primary Clinical Response or Non-response — NA endogenous anti-TNF serum level (µg/mL)
N/A N=69 Asthma Biomarker Study
Asthma
Primary: Level of Tumour Necrosis Factor-alpha (TNF-α) in Blood at Baseline (Visit 1) — 5.3; 9.3; 10.6; 15.7 pg/mL
N/A N=30 Nutritional Biomarkers of Sarcopenia
Sarcopenia
Primary: Resting and Maximum Plasma Leucine Concentration — 659; 755; 721; 95 micromoles per liter
Phase 2 N=100 A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
Rheumatoid Arthritis
Primary: Percentage of Participants Who Achieve American College of Rheumatology Response of 20 (ACR20 ) in Association With the Presence or Absence of the HLA-DRB1 *4 Allelic…
Phase 4 N=1,406 Biomarker and Genetic Predictors of Erenumab Treatment Response
Migraine
Primary: Percentage of Participants Achieving at Least a 50% Reduction From Baseline in Mean MMDs Over Months 4, 5, and 6 in Relation to mPRS — 54.9 percentage of participants…
N/A N=46 Breath Analysis Based Disease Biomarkers
Liver Diseases · Liver Cancer · COVID19
Primary: Breath Volatile Organic Compound Profiles — 11; 35 Participants
N/A N=260 LUME BioNIS: a Biomarker Study in Patients With NSCLC
Carcinoma, Non-Small-Cell Lung
Primary: Number of Participants With Overall Survival (OS) Event — 206 Participants
Phase 1 N=71 Metabolic Signatures and Biomarkers in Schizophrenia
Schizophrenia
Primary: Total Plasmalogen Levels in the Lipid Profile — 57.65; 59.57; 75 nmoles/gram — p=0.0149
Phase 3 N=53 Biological Markers of Response to Treatment in Major Depressive Disorder
Major Depressive Disorder
Primary: Serum Brain-derived Neurotrophic Factor (BDNF) Levels — 6077.270; 4393.24 pg/mL
N/A N=39 Biomarkers for Intestinal Permeability in Patients With Constipation
Intestinal Diseases · Irritable Bowel Syndrome · Constipation
Primary: Lactulose:C13 Mannitol Excretion Ratio 8-24hrs. — 0.01; 0.02 Ratio — p=0.87
Phase 2 N=158 Biomarkers of Lupus Disease: Serial Biomarker Sampling in Patients With Active Systemic Lupus Erythematosus (SLE)
Systemic Lupus Erythematosus
Primary: Time to Flare Comparing Patients With Moderate vs Severe Disease Activity at Baseline — 45; 71 days to flare — p=0.2738
N/A N=28 Evaluation of Blood/Imaging Based Biomarkers, Aromatase Inhibitor Induced Musculoskeletal Syndrome
Aromatase Inhibitor Induced Musculoskeletal Syndrome (AIMSS) · Breast Cancer
Primary: Oxylipin Levels — 10.2; 12.1; 12.3 pg/mL — p=0.684
N/A N=101 Choline Nutritional Status: Development of a Biomarker Panel
Healthy
Primary: Ratio of Liver Choline Pool Size by Isotope Dilution — 0.02357; 0.02403; 0.02184; 0.00023 isotopic enrichment ratio — p=0.0247
N/A N=7 Biomarkers in Chemotherapy-Induced Peripheral Neurotoxicity
CIPN - Chemotherapy-Induced Peripheral Neuropathy
Primary: Relative Change in % pO2 — 12.3; 19; 24; 25.3 change in % oxygenation
Phase 2 N=221 Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab
Colorectal Cancer
Primary: Progression Free Survival — 11.4; 5.9 Months — p=0.004
N/A N=133 Genetic and Biochemical Markers of Interferon-Induced Depression.
Depression
Primary: Phenotype and Genotype Based on Presence of Interferon Induced MDD. — 19; 114 participants — p=>0.05
N/A N=200 Novel Biomarkers of Thrombotic Risk
Myocardial Infarction
Primary: Cardiovascular Event - Myocardial Infarction, Stroke, Death — 17; 6 Participants — p=0.007
Phase 2 N=25 Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma
Renal Cell Carcinoma · Renal Cancer
Primary: Difference in Median Progression Free Survival Time Between Favorable and Unfavorable Biomarker Group
N/A N=40 Noninvasive Biomarkers of Metabolic Liver Disease 1.1
Nonalcoholic Steatohepatitis · Nonalcoholic Fatty Liver
Primary: Evaluation of Pooled Different-day, Different-operator Reproducibility of Shear Wave Speed Measurements — 30.7 Reproducibility coefficient (in %)